Correlation Between Design Therapeutics and GlaxoSmithKline PLC
Can any of the company-specific risk be diversified away by investing in both Design Therapeutics and GlaxoSmithKline PLC at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Design Therapeutics and GlaxoSmithKline PLC into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Design Therapeutics and GlaxoSmithKline PLC ADR, you can compare the effects of market volatilities on Design Therapeutics and GlaxoSmithKline PLC and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Design Therapeutics with a short position of GlaxoSmithKline PLC. Check out your portfolio center. Please also check ongoing floating volatility patterns of Design Therapeutics and GlaxoSmithKline PLC.
Diversification Opportunities for Design Therapeutics and GlaxoSmithKline PLC
-0.51 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Design and GlaxoSmithKline is -0.51. Overlapping area represents the amount of risk that can be diversified away by holding Design Therapeutics and GlaxoSmithKline PLC ADR in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on GlaxoSmithKline PLC ADR and Design Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Design Therapeutics are associated (or correlated) with GlaxoSmithKline PLC. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of GlaxoSmithKline PLC ADR has no effect on the direction of Design Therapeutics i.e., Design Therapeutics and GlaxoSmithKline PLC go up and down completely randomly.
Pair Corralation between Design Therapeutics and GlaxoSmithKline PLC
Given the investment horizon of 90 days Design Therapeutics is expected to generate 4.39 times more return on investment than GlaxoSmithKline PLC. However, Design Therapeutics is 4.39 times more volatile than GlaxoSmithKline PLC ADR. It trades about 0.01 of its potential returns per unit of risk. GlaxoSmithKline PLC ADR is currently generating about 0.01 per unit of risk. If you would invest 1,400 in Design Therapeutics on August 23, 2024 and sell it today you would lose (843.00) from holding Design Therapeutics or give up 60.21% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Design Therapeutics vs. GlaxoSmithKline PLC ADR
Performance |
| Timeline |
| Design Therapeutics |
| GlaxoSmithKline PLC ADR |
Design Therapeutics and GlaxoSmithKline PLC Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Design Therapeutics and GlaxoSmithKline PLC
The main advantage of trading using opposite Design Therapeutics and GlaxoSmithKline PLC positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Design Therapeutics position performs unexpectedly, GlaxoSmithKline PLC can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GlaxoSmithKline PLC will offset losses from the drop in GlaxoSmithKline PLC's long position.| Design Therapeutics vs. ZyVersa Therapeutics | Design Therapeutics vs. Sonnet Biotherapeutics Holdings | Design Therapeutics vs. Zura Bio Limited | Design Therapeutics vs. Phio Pharmaceuticals Corp |
| GlaxoSmithKline PLC vs. Novartis AG ADR | GlaxoSmithKline PLC vs. AstraZeneca PLC ADR | GlaxoSmithKline PLC vs. Roche Holding Ltd | GlaxoSmithKline PLC vs. Bristol Myers Squibb |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Complementary Tools
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |